The use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers may relate to the survival and walking ability in geriatric patients with hip fractures: a 1-year follow-up study
- PMID: 36978079
- PMCID: PMC10045946
- DOI: 10.1186/s12891-023-06362-5
The use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers may relate to the survival and walking ability in geriatric patients with hip fractures: a 1-year follow-up study
Abstract
Background: Many elder patients with hip fractures also suffered from hypertension. This study aims to explore the relationship between the use of ACEI or ARB and the outcomes of geriatric hip fractures.
Methods: All the patients were divided into four groups: non-users without hypertension, non-users with hypertension, ACEI users, and ARB users. The outcomes of patients in different groups were compared. LASSO regression and univariable Cox analysis were used for variable screening. Then Cox models and Logistics models were established to identify the relationships between the use of RAAS inhibitors and outcomes.
Results: ACER users (p = 0.016) and ARB users (p = 0.027) had a significantly lower survival probability than the non-users with hypertension. Non-users without hypertension, ACEI users, and ARB users may face lower 6-month and 1-year mortalities and higher 6-month and 1-year free walking rates compared with non-users with hypertension.
Conclusion: Patients with the use of ACEI or ARB may face a better prognosis of hip fractures.
Keywords: ACEI; ARB; Hip fractures; Hypertension; Prognosis.
© 2023. The Author(s).
Conflict of interest statement
The authors declare that they have no competing interests.
Figures



Similar articles
-
Fracture Risk and Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers.Calcif Tissue Int. 2022 Oct;111(4):396-408. doi: 10.1007/s00223-022-01004-9. Epub 2022 Jul 14. Calcif Tissue Int. 2022. PMID: 35833952 Free PMC article.
-
Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.Circ Res. 2020 Jun 5;126(12):1671-1681. doi: 10.1161/CIRCRESAHA.120.317134. Epub 2020 Apr 17. Circ Res. 2020. PMID: 32302265 Free PMC article.
-
Use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers associated with lower risk of COVID-19 in household contacts.PLoS One. 2021 Mar 2;16(3):e0247548. doi: 10.1371/journal.pone.0247548. eCollection 2021. PLoS One. 2021. PMID: 33651840 Free PMC article.
-
Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on major adverse cardiac events in patients with newly diagnosed type 2 diabetes: a nationwide study.Int J Cardiol. 2015 Nov 15;199:283-9. doi: 10.1016/j.ijcard.2015.07.053. Epub 2015 Jul 22. Int J Cardiol. 2015. PMID: 26218587
-
The use of renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: A systematic review and meta-analysis.J Med Virol. 2021 Mar;93(3):1370-1377. doi: 10.1002/jmv.26625. Epub 2020 Nov 10. J Med Virol. 2021. PMID: 33095513
References
-
- McHugh MA, Wilson JL, Schaffer NE, Olsen EC, Perdue A, Ahn J, et al. Preoperative Comorbidities Associated With Early Mortality in Hip Fracture Patients: A Multicenter Study. J Am Acad Orthop Surg. 2023;31(2):81–86. - PubMed
-
- Liu M, Ji S, Yang C, Zhang T, Han N, Pan Y, et al. Prealbumin as a nutrition status indicator may be associated with outcomes of geriatric hip fractures: a propensity score matching and 1-year follow-up study. Aging Clin Exp Res. 2022;34(12):3005–3015. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous